Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab - Genentech/Roche

Drug Profile

Pertuzumab - Genentech/Roche

Alternative Names: Anti-2C4 monoclonal antibody; Omnitarg; Perjeta; R-1273; RG-1273; rhuMab-2C4; rhuMAb2C4; Ro 436-8451/F01; RO-4368451-F01; RO4368451

Latest Information Update: 16 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Roche
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; International Breast Cancer Study Group; Japan Breast Cancer Research Group; Medica Scientia Innovation Research; Roche; West German Study Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Ovarian cancer
  • Phase II Brain metastases; Colorectal cancer
  • Discontinued Gastric cancer; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 20 Dec 2018 Roche initiates the phase III IMpassion050 trial for Breast Cancer (Combination therapy) in Germany, Italy, South Korea, Czech Republic (IV) (NCT03726879)
  • 17 Dec 2018 Registered for Breast cancer (Combination therapy, Early-stage disease, Adjuvant therapy) in China (IV)
  • 04 Dec 2018 Efficacy and adverse events data from the phase III PEONY trial in Breast cancer presented at the 41st Annual San Antonio Breast Cancer Symposium (SABCS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top